Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Gene expression test distinguishes between breast cancer patients at high or low risk of late recurrence

Prof Michael Gnant - Medical University of Vienna, Austria
Gene expression test distinguishes between breast cancer patients at high or low risk of late recurrence ( Prof Michael Gnant - Medical University of Vienna, Austria )
14 May 2013

Long-term effectiveness of SERMs for preventing breast cancer

Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK
Long-term effectiveness of SERMs for preventing breast cancer ( Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK )
14 May 2013

Closing the cancer divide: Implementing the diagonal approach

Dr Felicia Knaul - Harvard Medical School, Boston, USA
Closing the cancer divide: Implementing the diagonal approach ( Dr Felicia Knaul - Harvard Medical School, Boston, USA )
19 Apr 2013

Pelvic radiotherapy and androgen blockade for high risk prostate cancer

Dr Abdenour Nabid - Sherbrooke University, Quebec, Canada
Pelvic radiotherapy and androgen blockade for high risk prostate cancer ( Dr Abdenour Nabid - Sherbrooke University, Quebec, Canada )
25 Feb 2013

Results of a randomised phase 2 study of PD 0332991

Dr Richard Finn - Universtity of California, Los Angeles, USA
Results of a randomised phase 2 study of PD 0332991 ( Dr Richard Finn - Universtity of California, Los Angeles, USA )
17 Dec 2012

The AZURE translational study

Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
The AZURE translational study ( Prof Robert Coleman	 - Weston Park Hospital, University of Sheffield, UK )
14 Dec 2012

Prognostic signatures in colon cancer

Dr Ramon Salazar – Catalan Institut of Oncology, Barcelona, Spain
Prognostic signatures in colon cancer ( Dr Ramon Salazar – Catalan Institut of Oncology, Barcelona, Spain )
7 Dec 2012

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA
HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )
6 Dec 2012

Gestational trophoblastic disease tumours in high risk patients

Dr Michael Seckl – Charing Cross Hospital, Imperial College London, UK
Gestational trophoblastic disease tumours in high risk patients ( Dr Michael Seckl – Charing Cross Hospital, Imperial College London, UK )
30 Oct 2012

State of PARP inhibitors and anti-angiogenics

Prof Stan Kaye – Royal Marsden Hospital, London, UK
State of PARP inhibitors and anti-angiogenics ( Prof Stan Kaye – Royal Marsden Hospital, London, UK )
29 Oct 2012

Defining and advancing individualised medicine

Prof Anil Sood – MD Anderson Cancer Centre, Houston, USA
Defining and advancing individualised medicine ( Prof Anil Sood – MD Anderson Cancer Centre, Houston, USA )
29 Oct 2012

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012